整合素拮抗剂治疗炎症性肠病的研究进展  

Advances in treatment of inflammatory bowel disease with integrin antagonists

作　　者：金美静 程慧 冯晓莹[2] JIN Mei-jing;CHENG Hui;FENG Xiao-ying(Department of Gastroenterology,Dalian Jinzhou District First People's Hospital,Dalian LIAONING 116027,China;Department of Gastroenterology,the Second Hospital of Dalian Medical University,Dalian LIAONING 116023,China)

机构地区：[1]大连市金州区第一人民医院消化科,辽宁大连116027 [2]大连医科大学附属第二医院消化科,辽宁大连116023

出　　处：《中国新药与临床杂志》2024年第11期814-819,共6页Chinese Journal of New Drugs and Clinical Remedies

基　　金：大连市科技惠民基金(2023JJ13SN053)。

摘　　要：整合素在介导淋巴细胞进入肠道从而导致炎症性肠病(IBD)发生的过程中扮演着重要的角色,其与相应配体结合可介导淋巴细胞的肠道归巢和滞留。目前,抗整合素药物维得利珠单抗已应用于临床,其他几种抗整合素药物也正处于研发过程中,如阿利鲁单抗、AJM300、PTG-100以及milategrast。临床研究表明,肠道选择性的抗整合素药物可以作为治疗IBD的一种安全且有效的选择。Integrins play an important role in mediating the entry of lymphocytes into the intestines leading to the development of inflammatory bowel disease(IBD),and their binding to the corresponding ligands mediates the intestinal homing and retention of lymphocytes.Currently,the anti-integrin drug vedolizumab has been used in clinical practice,and several other anti-integrin drugs are under development,such as abrilumab,AJM300,PTG-100,and milategrast.Clinical studies have shown that gut-selective anti-integrin agents may be a safe and effective option for the treatment of IBD.

关 键 词：整合素 炎症性肠病 溃疡性结肠炎 克罗恩病 

分 类 号：R971[医药卫生—药品]